Preclinical reports counsel that retatrutide might affect being overweight-related cancer progression. In a review led by Marathe et al., retatrutide-induced weight loss diminished tumor engraftment, delayed tumor onset, and noticeably attenuated tumor development in pancreatic and lung cancer types, with bigger tumor suppression compared to GLP-1